NEW YORK, April 2, 2026
Intelligent Bio Solutions Inc. has achieved a critical milestone in its regulatory journey by completing its clinical Cut-off Study for the Intelligent Fingerprinting Drug Screening System, strengthening its path toward FDA 510(k) clearance and entry into the multi-billion-dollar U.S. drug screening market. The study, conducted on 40 adult participants, evaluated codeine detection thresholds using the company’s innovative fingerprint-based testing approach and delivered results on schedule, reinforcing confidence in the system’s clinical reliability and regulatory readiness.
Clinical Validation Strengthens Regulatory Pathway
The completed Cut-off Study represents a foundational component of the FDA submission process, demonstrating the system’s ability to accurately detect recent codeine use through non-invasive fingerprint sweat analysis. The study utilized the company’s proprietary drug screening cartridge in combination with the DSR-Plus fluorescence reader, with results benchmarked against an FDA-cleared predicate device and further validated through LC-MS/MS (liquid chromatography-tandem mass spectrometry).
This robust comparative methodology ensures alignment with regulatory expectations for analytical performance and accuracy, significantly enhancing the credibility of the submission package. The ability to generate rapid, reliable results without invasive sampling positions this technology as a disruptive alternative to traditional methods such as urine, blood, and oral fluid testing, particularly in regulated workplace environments.
Expansion into Multi-Phase Clinical Program
Advertisement
Building on this success, the company has initiated the second phase of its clinical program, which includes a multi-site Method Comparison and Usability Study designed to evaluate system performance across real-world clinical settings. This phase will assess accuracy, ease of use, and operational efficiency when handled by intended users, a key requirement for FDA clearance and commercial scalability. The study is expected to conclude by June 2026, followed by an Interference Study scheduled for completion by July 2026, which will test the system’s resilience in the presence of environmental and biological interfering substances.
These additional validation layers are critical for demonstrating device robustness and reliability in diverse workplace conditions, including industries such as construction, transportation, and manufacturing, where rapid drug screening is essential for safety compliance.
Market Opportunity and Technological Impact
The U.S. drug screening market, valued at billions annually, presents a substantial commercial opportunity, particularly across segments such as workplace safety, criminal justice, pain management, and substance abuse programs. Intelligent Bio Solutions’ fingerprint-based drug testing technology offers several competitive advantages, including non-invasive sample collection, near real-time detection of impairment, and portability for on-site testing. Unlike conventional tests that may detect historical drug use, this system is specifically designed to identify recent consumption, providing more actionable insights for employers and regulators.
Additionally, the platform delivers results in under ten minutes, significantly reducing downtime and improving operational efficiency. The company’s leadership has emphasized that the timely completion of the study keeps them firmly on track for FDA submission and planned U.S. commercialization, potentially transforming drug testing protocols across safety-critical industries.
With expanding clinical validation, strong regulatory momentum, and a differentiated technology platform, Intelligent Bio Solutions is positioning itself at the forefront of next-generation drug screening innovation, aiming to redefine standards in speed, accuracy, and usability while unlocking significant value in a rapidly evolving MedTech landscape.
Source: Intelligent Bio Solutions Inc. press release
